Lupin Limited

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company with presence in over 100 countries and turnover of US $ 2.5 billion. We focus on development of difficult to develop, specialty and niche generics in the fields of CNS, anti-infectives, respiratory, CVS, urology, pain and diabetes.  With continued investments towards internalizing technology platforms in the fields of biotechnology, complex/long acting injectables, inhalation, Lupin is well positioned to become a global pharmaceutical powerhouse with a broad specialty portfolio. Several inhalation products (MDI/DPIs) have already been filed globally and first filings for Europe to begin in the very near future. Development of complex injectables in the diabetes, oncology, CNS completed and global filings began in 2019. Lupin has an enviable quality and delivery track record. We consistently achieve an OTIF of 95% or more.

  • IN
  • 2019
    On CPhI since
Contact info

Lupin Limited Resources